FEATURED INSIGHTSMedical CommunicationsOncology UpdatesWhite Papers White Paper: Immune Checkpoint Inhibitors for the Treatment of Cancer By Zachary Moore | FEATURED INSIGHTS, Medical Communications, Oncology Updates, White Papers
Approval BlogMedical CommunicationsOncology Updates Durvalumab receives FDA-approval as a consolidation treatment for Stage III NSCLC By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Market AccessMarket ResearchOncology Updates Take a Look Into Our Market Access Work By Cadence Team | Market Access, Market Research, Oncology Updates
Market AccessMarket ResearchOncology Updates Are you getting the most out of the Specialty Pharmacies (SPs) in your network / HUB? By Cadence Team | Market Access, Market Research, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates Dabrafenib and Trametinib for the Treatment of BRAF V600E-positive Anaplastic Thyroid Cancer By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates Tisagenlecleucel for Patients with Relapsed or Refractory Large B-cell Lymphoma By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates Dabrafenib and Trametinib for Adjuvant Treatment of BRAF V600E/K-Positive Melanoma By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Oncology Updates Leveraging Innovation Centers to Re-prime the Development Pump! By Cadence Team | Oncology Updates
Approval BlogMedical CommunicationsOncology Updates Osimertinib for the Frontline Treatment of EGFR-mutant NSCLC By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
Approval BlogMedical CommunicationsOncology Updates Combination of Nivolumab Plus Ipilimumab for Frontline Treatment of Renal Cell Carcinoma By Zachary Moore | Approval Blog, Medical Communications, Oncology Updates
